Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on July 26, 2018. The filing details the entry into a Material Definitive Agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 1,256,118 units, each consisting of one share of common stock and one warrant to purchase one share.
- Purchase Price: $2.86 per unit.
- Gross Proceeds: Approximately $3.6 million (calculated as 1,256,118 units x $2.86).
- Net Proceeds: Approximately $3.3 million, net of placement agent fees and estimated offering expenses.
- Warrant Terms: Initial exercise price of $3.00 per share; exercisable six months after issuance; expires five years after becoming exercisable.
- Placement Agent Fees: 6% of gross proceeds from investors introduced by Chardan Capital Markets, LLC. No fee applies to sales to management, board members, or existing shareholders.
- Expense Reimbursement: Up to $25,000 for legal fees and expenses of the placement agent.
Material Changes and Participation
The Company completed the offering on July 31, 2018. Significant participation occurred from internal stakeholders:
- Management Participants: William Annett (CEO), Mitchell Levine (CFO), and Lyndal Hesterberg (SVP - R&D).
- Board Participants: Cavan Redmond, Andrew Arno, Ronald Andrew, and Andrew Last.
The filing does not provide comparative financial data (revenue, profit, cash flow, or debt levels) for the prior period, as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Ownership Limitations: Warrant holders cannot exercise if they would beneficially own more than 4.99% of the outstanding common stock immediately after exercise.
- Fundamental Transaction Rights: In the event of a fundamental transaction, holders may require the Company to purchase warrants at their Black Scholes value. If the transaction is outside the Company's control, holders receive consideration equivalent to that offered to common stockholders.
- Adjustments: Warrant exercise prices and share counts are subject to adjustment for stock splits, dividends, and similar events.
Investor Verification Checklist
- Verify the final net proceeds received by the Company after all closing costs.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Confirm the dilution impact of the 1,256,118 new shares and potential future warrant exercises.
- Check the Company's cash position post-offering to assess runway for operations.
- Review the press release (Exhibit 99.1) for management's stated use of proceeds.